GlassScriptPhysician profile
Brenda L Deliz
NPI 1023068467
$8,989.38
in general payments reported to CMS, 2019-2025
22 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $128 · 2021: $1,052 · 2022: $24.03 · 2023: $5,820 · 2024: $979 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Food and Beverage | $1,900.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $5,516.13 | 2023-2024 | Emflaza |
| Janssen Pharmaceuticals, INC | $1,020.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $365.83 | 2019-2025 | |
| Ns Pharma, INC. | $295.89 | 2023-2025 | Viltepso |
| Biogen, INC. | $271.09 | 2020-2025 | Spinraza, Qalsody, Vumerity |
| Alexion Pharmaceuticals, INC. | $246.27 | 2024-2025 | Ultomiris |
| Amgen INC. | $177.97 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $167.44 | 2019-2023 | Evrysdi |
| Tanabe Pharma America, INC. | $167.14 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $152.31 | 2019 | |
| Argenx US, INC. | $124.92 | 2025 | Vyvgart |
| Eisai INC. | $123.79 | 2024 | |
| Abbvie INC. | $102.06 | 2019-2023 | Qulipta, Ubrelvy |
| Genentech, INC. | $54.14 | 2024 | Evrysdi |
| E.R. Squibb & Sons, L.L.C. | $42.12 | 2023-2024 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $34.24 | 2025 | |
| Sarepta Therapeutics, INC. | $33.41 | 2024 | Elevidys |
| Eli Lilly Export S.A. Puerto Rico Branch | $23.22 | 2020 | |
| Banner Life Sciences, LLC | $22.37 | 2023 | |
| Allergan, INC. | $22.36 | 2019 | |
| Akcea Therapeutics, INC. | $14.95 | 2019 | |
| Acadia Pharmaceuticals INC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Deliz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.